In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 251 to 275 of 301

TitleTypeExpected publication date
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]Technology appraisal guidanceTBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidance
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]Technology appraisal guidanceTBC
Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer [ID6758]Technology appraisal guidanceTBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]Technology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]Technology appraisal guidanceTBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]Technology appraisal guidance
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]Technology appraisal guidanceTBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Technology appraisal guidanceTBC
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]Technology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]Technology appraisal guidance
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]Technology appraisal guidanceTBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Technology appraisal guidanceTBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]Technology appraisal guidance
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All